Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
- PMID: 32861965
- PMCID: PMC7444940
- DOI: 10.1016/j.biopha.2020.110668
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
Abstract
Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual outbreak in Wuhan, China, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is currently no licensed antiviral treatment available to prevent human CoV infection. The widespread clinical use and existing knowledge on antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine in the treatment of previous epidemic diseases, namely, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), may be helpful in the combat with novel SARS-CoV-2 infection. Recent clinical evidence didn't confirm the beneficial role of lopinavir/ritonavir and chloroquine/hydroxychloroquine for COVID-19 patients and their use was reassessed. We provide an overview of the current evidence into the mechanisms of action of these available drugs which are repurposed for treatment of the new virus. Available data identifies remdesivir as an adenosine analogue that can target the RNA-dependent RNA polymerase and block viral RNA synthesis. It has been a promising antiviral drug against a wide array of RNA viruses. 3CLpro is a major CoV protease that cleaves the large replicase polyproteins during viral replication and can be targeted by the protease inhibitor lopinavir/ritonavir but the clinical effects are controversial. Chloroquine/Hydroxychloroquine could impair the replication of SARSCoV-2 by multiple mechanisms and their immunomodulatory properties could ameliorate clinical manifestations that are mediated by immune reactions of the host although its beneficial effects are under question and need to be proven at the clinical level. Existing in vitro and in vivo evidence delineate the molecular mechanisms of these drugs in CoV-infected cells. Numerous studies demonstrated the ability of remdesivir to inhibit SARS-CoV-2 replication but future research would be needed to understand the exact mode of action of lopinavir/ritonavir and chloroquine/hydroxychloroquine in SARS-CoV-2 infected cells and to use this knowledge in the treatment of the current COVID-19.
Keywords: Antiviral mechanism; Chloroquine/hydroxychloroquine; Lopinavir/ritonavir; Remdesivir; SARS-CoV-2.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
KHU, EPF and VGP are employees of Tchaikapharma High Quality Medicines Inc.
Figures
Similar articles
-
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117. Curr Med Chem. 2020. PMID: 32297571
-
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00399-20. doi: 10.1128/AAC.00399-20. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32152082 Free PMC article. Review.
-
Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.J Cell Biochem. 2022 Feb;123(2):347-358. doi: 10.1002/jcb.30174. Epub 2021 Nov 6. J Cell Biochem. 2022. PMID: 34741481 Free PMC article.
-
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.Antimicrob Agents Chemother. 2020 Aug 20;64(9):e01101-20. doi: 10.1128/AAC.01101-20. Print 2020 Aug 20. Antimicrob Agents Chemother. 2020. PMID: 32631826 Free PMC article. Review.
-
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.SLAS Discov. 2020 Dec;25(10):1108-1122. doi: 10.1177/2472555220958385. Epub 2020 Sep 17. SLAS Discov. 2020. PMID: 32942923 Free PMC article. Review.
Cited by
-
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomed Pharmacother. 2022 Mar;147:112700. doi: 10.1016/j.biopha.2022.112700. Epub 2022 Feb 4. Biomed Pharmacother. 2022. PMID: 35131656 Free PMC article. Review.
-
Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.Clin Immunol. 2022 Nov;244:109093. doi: 10.1016/j.clim.2022.109093. Epub 2022 Aug 6. Clin Immunol. 2022. PMID: 35944881 Free PMC article. Review.
-
SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure.J Clin Med. 2020 Dec 15;9(12):4057. doi: 10.3390/jcm9124057. J Clin Med. 2020. PMID: 33334050 Free PMC article. Review.
-
Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms.Molecules. 2021 Nov 16;26(22):6900. doi: 10.3390/molecules26226900. Molecules. 2021. PMID: 34833991 Free PMC article.
-
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2.Top Curr Chem (Cham). 2023 Jun 15;381(5):22. doi: 10.1007/s41061-023-00432-x. Top Curr Chem (Cham). 2023. PMID: 37318607 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous